Enliven Therapeutics (ELVN) Analyst & Key Data

Analyst Consensus

Buy12 analysts

Buy

Updated Sep 12, 2026

Total Analysts12

Buy

9

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$54.32

Median Target+32.55%

$72.00

Potential upside vs current price

DCF Value-96.87%

$1.70

Potential downside vs current price

Current Stock Price

$54.32

Median Target+32.55%

$72.00

Potential upside vs current price

DCF Value-96.87%

$1.70

Potential downside vs current price

Analyst Consensus

Buy12 analysts

Buy

Updated Sep 12, 2026

Total Analysts12

Buy

9

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$54.32

Median Target+32.55%

$72.00

Potential upside vs current price

DCF Value-96.87%

$1.70

Potential downside vs current price

Current Stock Price

$54.32

Median Target+32.55%

$72.00

Potential upside vs current price

DCF Value-96.87%

$1.70

Potential downside vs current price

Enliven Therapeutics, Inc.